
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitor... Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 2.43 | 2.63 | 2.06 | 15996 | 2.3737166 | CS |
4 | -1.77 | -42.1428571429 | 4.2 | 7.3 | 2.01 | 729118 | 5.97007722 | CS |
12 | -3.06 | -55.737704918 | 5.49 | 7.3 | 2.01 | 261420 | 5.91539266 | CS |
26 | -4.27 | -63.7313432836 | 6.7 | 7.59 | 2.01 | 132770 | 5.90909908 | CS |
52 | -14.07 | -85.2727272727 | 16.5 | 18.5 | 2.01 | 154412 | 10.13632483 | CS |
156 | -59.57 | -96.0806451613 | 62 | 92.5 | 2.01 | 195632 | 23.67694979 | CS |
260 | -391.82 | -99.3836398224 | 394.25 | 449.75 | 2.01 | 224888 | 71.21215238 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions